Rain Oncology
A late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit.
The USA-based company's strategy includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology.
Rain’s product candidate, milademetan, is a small molecule, oral inhibitor of the MDM2-p53 complex that reactivates p53.
Latest Rain Oncology News & Features
18 December 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze